Alnylam cuts Amvuttra sales forecast ~$200M after misjudging market demand; stock drops premarket.
July 30, 2026 09:25 AM EDTUpdated 09:54 AM
Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock
Max Gelman
Alnylam’s second-quarter earnings report Thursday did little to assuage investor concerns in what has already been a difficult year for the company.
The drugmaker
Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and…
Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a lowered…
Alnylam's stock is down 30% in 2026 despite Amvuttra's success. Wainua's Phase 3 failure raised doubts about RNAi silencers like…
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main…
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close…
Alnylam stock rises after a $2 billion AI-driven RNAi drug discovery collaboration with Inceptive as analysts maintain bullish…
